UCB’s $1.15B Neurona Therapeutics acquisition is a high-stakes bet on cell therapy in epilepsy. The bigger question: can biotech move from suppressing seizures to repairing brain circuits?
https://biotech.industryexaminer.com/ucb-neurona-epilepsy-cell-therapy-bet/
#Biotech #UCB #NeuronaTherapeutics #Epilepsy #CellTherapy #TechNews






